



(51) International Patent Classification:

C12N 15/113 (2010.01) *A61K 31/713* (2006.01)
C12N 15/861 (2006.01) *A61K 48/00* (2006.01)
C12N 15/86 (2006.01) *A61K 47/42* (2017.01)
C12N 15/85 (2006.01) *A61P 1/16* (2006.01)
A61K 31/7105 (2006.01)

(21) International Application Number:

PCT/US2017/026217

(22) International Filing Date:

5 April 2017 (05.04.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/318,728 5 April 2016 (05.04.2016) US
 62/319,169 6 April 2016 (06.04.2016) US
 62/400,583 27 September 2016 (27.09.2016) US

(71) Applicant: UNIVERSITY OF MASSACHUSETTS
[US/US]; 225 Franklin Street, Boston, MA 02110 (US).

(72) Inventors: SZABO, Gyongyi; c/o University of Massachusetts Medical School, Office of Technology Management, 55 Lake Avenue N., Worcester, MA 01655 (US). GAO, Guangping; 4 Edward Dunn Way, Westborough, MA 01581 (US). SATISHCHANDRAN, Abhishek; c/o University of Massachusetts Medical School, Office of Technology Management, 55 Lake Avenue N., Worcester, MA 01655 (US).

(74) Agent: YOUNG, Daniel; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210-2206 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: COMPOSITIONS AND METHODS FOR SELECTIVE INHIBITION OF GRAINYHEAD-LIKE PROTEIN EXPRESSION




FIG. 8

(57) Abstract: In some aspects, the disclosure relates to methods and compositions for modulation of miR-122 expression in a cell or a subject. In some embodiments, methods and compositions described by the disclosure are useful for the treatment of liver-associated diseases (e.g., chronic liver disease, alcoholic liver disease).

COMPOSITIONS AND METHODS FOR SELECTIVE INHIBITION OF GRAINYHEAD-LIKE PROTEIN EXPRESSION

RELATED APPLICATION

5 This application claims the benefit of the filing date of U.S. Provisional Application No. 62/318,728, entitled "COMPOSITIONS AND METHODS FOR SELECTIVE INHIBITION OF GRAINYHEAD-LIKE 2 PROTEIN EXPRESSION," filed April 5, 2016; U.S. Provisional Application No. 62/319,169, entitled "COMPOSITIONS AND METHODS FOR SELECTIVE INHIBITION OF GRAINYHEAD-LIKE 2 PROTEIN EXPRESSION,"
10 filed April 6, 2016; and U.S. Provisional Application No. 62/400,583, entitled "COMPOSITIONS AND METHODS FOR SELECTIVE INHIBITION OF GRAINYHEAD-LIKE 2 PROTEIN EXPRESSION," filed September 27, 2016, the contents of each which are incorporated herein by reference in their entireties.

FEDERALLY SPONSORED RESEARCH

15 This invention was made with government support under grant number R01-AA020744 and F30AA022283, awarded by the National Institutes of Health. The government has certain rights in the invention.

BACKGROUND OF INVENTION

20 Chronic, excessive alcohol consumption accounts for nearly 50% of all chronic liver disease deaths in the western world. Generally, chronic liver disease involves a process of progressive destruction and regeneration of the liver parenchyma leading to fibrosis and cirrhosis. Examples of chronic liver disease include inflammation (chronic hepatitis), liver cirrhosis, and hepatocellular carcinoma. Treatment of chronic liver disease may involve
25 complex and expensive treatment regimens and, in certain cases, requires liver transplantation. Improved methods and compositions for treatment of liver diseases are needed.

SUMMARY OF INVENTION

30 In some aspects, the disclosure relates to methods and compositions for the treatment of liver-associated diseases (*e.g.*, chronic liver disease, alcoholic liver disease, *etc.*). The disclosure is based, in part, on the discovery that certain forms of grainyhead-like transcriptional regulators (GRHL) (*e.g.*, spliced form of GRHL2) modulate (*e.g.*, inhibit)

expression of miR-122 in liver cells. In some embodiments, miR-122 expression is reduced in cells, or subjects, having (*e.g.*, characterized by) chronic liver disease. Accordingly, in some aspects, the disclosure provides a method for modulating miR-122 expression in a cell, the method comprising: contacting a cell with an effective amount of a grainyhead-like transcriptional regulator (GRHL) modulating agent. In some embodiments, the GRHL modulating agent is an inhibitory nucleic acid that inhibits expression of a grainyhead-like transcriptional regulator (GRHL). In some embodiments, inhibition of a GRHL results in an increase in expression of miR-122 in the cell.

The disclosure relates, in part, to the discovery that grainyhead-like transcriptional regulator (GRHL) (*e.g.*, the spliced form of GRHL2) modulates (*e.g.*, inhibits) expression of miR-122, which modulates expression of hypoxia-inducible factor 1 α (HIF1 α). For example, in some embodiments, expression of grainyhead-like regulator (*e.g.*, spliced form of GRHL2) inhibits expression of miR-122 and results in increased expression of HIF-1 α . Thus, in some aspects, the disclosure provides a method for inhibiting hypoxia-inducible factor 1 α (HIF-1 α) expression in a cell (*e.g.*, a liver cell of a subject having a liver-associated disease), the method comprising: increasing expression of miR-122 in the cell. In some embodiments, expression of miR-122 is increased in the cell by delivering to the cell a nucleic acid engineered to express miR-122. In some embodiments, inhibition of a GRHL, or expression of miR-122, results in a decrease in expression of HIF-1 α in the cell.

In some aspects, the disclosure relates to methods and compositions for treatment of liver-associated diseases (*e.g.*, chronic liver disease). In some embodiments, the liver-associated disease is alcoholic liver disease (ALD), cirrhosis, hepatitis A, hepatitis B, hepatitis C, hepatocellular carcinoma (HCC), or fibrosis of the liver. In some embodiments, the liver-associated disease results in hepatic lipid accumulation in the subject. Accordingly, in some aspects, the disclosure provides a method for treating a liver-associated disease, the method comprising administering to a subject having or suspected of having a liver-associated disease an effective amount of a grainyhead-like (GRHL) transcriptional regulator modulating agent.

In some aspects, the disclosure provides a method for treating a liver-associated disease, the method comprising: administering to a subject having or suspected of having a liver-associated disease an effective amount of an agent that increases expression of miR-122 in liver cells of the subject. In some embodiments, the agent is an inhibitor of a grainyhead-like (GRHL) transcriptional regulator (*e.g.*, an inhibitory RNA targeting GRHL). In some embodiments, the agent inhibits expression of grainyhead-like 2 (GRHL2) transcriptional

regulator, optionally spliced GRHL2. In some embodiments, the agent is a nucleic acid engineered to express miR-122.

Generally, a grainyhead-like (GRHL) transcriptional regulator modulating agent or a nucleic acid engineered to express miR-122 can be delivered to a cell or a subject by any suitable means known in the art. However, in some embodiments of methods described by the disclosure, a grainyhead-like (GRHL) transcriptional regulator modulating agent or a nucleic acid engineered to express miR-122 is delivered as a component (*e.g.*, as a transgene encoded by) a recombinant AAV (rAAV). In some embodiments, the disclosure provides a method for treating a liver-associated disease, the method comprising: administering to a subject having or suspected of having a liver-associated disease an effective amount of a recombinant adeno-associated virus (rAAV) comprising a transgene encoding miR-122.

BRIEF DESCRIPTION OF DRAWINGS

FIGs. 1A-1F show chronic alcohol use is associated with reduced miR-122 expression. Expression of miR-122 in (FIG. 1A) total human liver (n=9-12), murine (FIG. 1B) total liver (n=8-14), (FIG. 1C) murine hepatocytes and CD45+ liver mononuclear cells (LMNCs) of pair-fed and alcohol-fed mice (n=5). (FIG. 1D) Hepatic miR-122 expression (FIG. 1C), serum ALT (FIG. 1E) and H&E histology and triglyceride concentrations (Fig. 1F) from the total livers of scrambled or miR-122-TuD treated WT mice after 5 weeks of control (PF) or alcohol (Et) diet. * $P < 0.05$, ** $P < 0.005$, *** $P < 0.0005$ by Student's *t* test or two-way ANOVA (n=6-14). Scale bars; 100 μ m.

FIGs. 2A-2F show chronic alcohol is associated with increased HIF-1 α expression. Expression of HIF-1 α and correlation to miR-122 expression in (FIG. 2A) human livers (n=9-12), and (FIG. 2B) murine hepatocytes (n=8-14). (FIG. 2C) The effect of miR-122-5p or scrambled oligonucleotide on luciferase activity from pmirCHECK-transfected HEK293T cells expressing the WT (3'UTR) of HIF-1 α (n=8). (FIG. 2D) HIF-1 α mRNA in the total livers, (FIG. 2E) HIF-1 α Electro-Mobility Shift Assay (EMSA) of hepatocyte nuclei, and (FIG. 2F) PPAR γ mRNA in total livers isolated from Scr or miR-122-TuD treated WT mice after 5 weeks of PF or Et diet. * $P < 0.05$, ** $P < 0.005$, *** $P < 0.0005$ by Student's *t* test or two-way ANOVA (n=8-14).

FIGs. 3A-3E show miR-122 mediates HIF-1 α steatosis and liver injury through HIF-1 α *in vivo* assessment of (FIG. 3B) H&E histology, (FIG. 3C) steatosis score, (FIG. 3D) triglyceride concentrations, (FIG. 3E) PPAR γ and (FIG. 3A) serum ALT levels, in WT or

HIF-1 α ^{hep-/-} mice. **P* < 0.05, ***P* < 0.005, ****P* < 0.0005 by Student's *t* test or two-way ANOVA (n=6-14). Scale bars; 100 μ m.

FIGs. 4A-4C show miR-122 loss mediates hepatic inflammation and fibrosis through HIF-1 α . Assessment of hepatic inflammation by (FIG. 4A) scoring of inflammatory cell infiltration, liver IL-1 β and MCP-1 protein from total liver lysates. Histological assessment of fibrosis by Sirius Red (FIG. 4B) staining. (FIG. 4C) Scoring of collagen deposition, qPCR analysis of stellate cell activation markers Collagen1a1 (coll1a1) and α -smooth muscle actin (Acta2). **P* < 0.05, ***P* < 0.005, ****P* < 0.0005 by Student's *t* test or two-way ANOVA (n=6-14). Scale bars: 100 μ m.

FIGs. 5A-5E show treatment with scAAV8-miR-122-OX protects from ALD via inhibition of HIF-1 α expression. (FIG. 5A) miR-122, (FIG. 5B) serum ALT, (FIG. 5C) H&E histology and hepatic triglycerides, (FIG. 5D) hepatocyte HIF-1 α expression and activity, (FIG. 5E) MCP-1 and IL-1 β protein treated from liver of either Et-fed WT mice treated with scAAV8-Scr or scAAV8-miR-122-OX vectors. (n=8-12) Scale bars; 100 μ m.

FIGs. 6A-6F show grainyhead-like 2 inversely correlates with miR-122 expression in human livers. Pri-miR-122 expression in (FIG. 6A) human livers (n=10-12), alcohol-fed WT murine (FIG. 6B) livers (n=8-12) and hepatocytes (n=5). Pri-miR-122 expression in hepatocytes from pair-fed and alcohol-fed treated with either (FIG. 6C) miR-122-TuD, or miR-122-OX treated mice, and HIF-1 α ^{hep-/-} mice. Chromosome immunoprecipitation-qPCR (ChIP-qPCR) of the GRHL binding results presented as % input of (FIG. 6D) GRHL2 and respective IgG controls. (FIG. 6E) GRHL2 mRNA expression in murine livers. (FIG. 6F) GRHL2 mRNA expression and correlation with miR-122 expression in human livers. **P* < 0.05, ***P* < 0.005, ****P* < 0.0005 by Student's *t* test or two-way ANOVA (n=6-14).

FIGs. 7A-7F show alcohol inhibits miR-122 in hepatocytes via alternatively spliced GRHL2. GRHL2 histology in (FIG. 7A) murine and (FIG. 7B) human livers. Scale bars; full-size=100 μ m, inset=50 μ m. (FIG. 7C) Immunostaining staining of isolated primary hepatocytes from PF- and Et-fed mice. Scale bars; PF=10 μ m, Et=10 μ m, Et+IgG=7.5 μ m. Representative immunoblots for (FIG. 7D) murine (n=8) and (FIG. 7E) human (n=10) GRHL2 from total liver lysate. (FIG. 7F) The effect of GRHL2-FL or GRHL2-S miR-122 promoter activity (n=4). **P* < 0.05, ***P* < 0.005, ****P* < 0.0005 by Student's *t* test.

FIG. 8 shows a proposed model. Chronic alcohol increases expression and splicing of GRHL in hepatocytes, inhibiting miR-122 transcription. The decrease in miR-122 increases HIF-1 α mRNA driving liver injury, steatosis, inflammation, and fibrosis. Restoration of miR-122 expression leads to decreased HIF-1 α expression driving liver recovery.

FIGs. 9A-9B show HIF-1 α mRNA expression in human hepatocytes treated with either (FIG. 9A) miR-122 mimic or (FIG. 9B) anti-miR-122 inhibitor. P value calculated by Student's *t* test (n=12).

FIGs. 10A-10G show (FIG. 10A) 5-week Lieber Di-Carli chronic alcohol feeding model. Hepatic expression of (FIG. 10B) miR-122, (FIG. 10C) Serum ALT F4/80, (FIG. 10D) CD68, (FIG. 10E) pro-IL1 β , (FIG. 10F) MCP1, and (FIG. 10G) Tgf β 1 in scrambled or miR-122-TuD treated WT or HIF-1 α ^{hep-/-} mice after 5 weeks of control (PF) or alcohol (Et) diet. **P* < 0.05, ***P* < 0.005, ****P* < 0.0005 by Student's *t* test or two-way ANOVA (n=6-14).

FIGs. 11A-11F shows (FIG. 11A) Serum ALT from week 2, of a Liber DeCarli chronic alcohol feeding model. (FIG. 11B) Gaussia Luciferase (Gluc) activity measured weekly from (n=3-5) alcohol-fed mice given 6x10¹¹ viral particles by tail vein injection. (FIG. 11C) Schematic representation of scAAV8-miR-122-OX treatment model. Liver (FIG. 11D) TNFa protein, (FIG. 11E) Mcp1, and (FIG. 11F) IL-1 β expression. **P* < 0.05, ***P* < 0.005, ****P* < 0.0005 by Student's *t* test or two-way ANOVA.

FIGs. 12A-12C show expression of (FIG. 12A) Ppar γ , (FIG. 12B) HNF4 α , and (FIG. 12C) HNF6 in the livers of PF and Et-fed mice.

FIGs. 13A-3B show a (FIG. 13A) a schematic representation of miR-122 promoter, transcription start site (TSS), Grainyhead (GRHL) dimer binding site and location of pre-miR-122 stem-loop. (FIG. 13B) Schematic representation of GRHL1 and GRHL2 full length and spliced protein products, denoting the N-terminal Transactivation domain in the FL variants, the central DNA binding domain, and the C-terminal Dimerization domain. Percentages indicate similarity between indicated domains of the splice variants and full length protein products.

FIGs. 14A-14C show Grainyhead-like 1 and 2 immunohistochemistry. Immunostaining for (FIG. 14A) GRHL1 and (FIG. 14B) GRHL2 in FFPE liver sections from healthy controls and alcoholic cirrhosis patients. (FIG. 14C) Immunostaining of FFPE liver sections from PF- and Et-fed mice. Scale bars; full-size=100 μ m, inset=50 μ m.

FIGs. 15A-15D show that chronic alcohol induces alternative splicing of GRHL1 and GRHL2. Representative immunoblot for GRHL1 from (FIG. 15A) human (n=5) and (FIG. 15B) murine (n=5) from total liver lysate. Representative immunoblot for GRHL2 from (FIG. 15C) human (n=5) and (FIG. 15D) murine (n=5) from total liver lysate. β -actin was used as a loading control. **P* < 0.05, ***P* < 0.005, ****P* < 0.0005 by Student's *t* test.

FIGs. 16A-16B show the role of grainyhead isoforms on miR-122 expression. (FIG. 16A) Firefly luciferase activity driven by either a WT, Mut (mutated GRHL site, or truncated

human miR-122 promoter in HUH7 cells. Each promoter was co-transfected with human cDNA clones of either the GRHL1-FL, GRHL2-FL, or GRHL2-S alone, or in combination. (FIG. 16B) expression of pri-miR-122 in primary human hepatocytes containing ectopically expressed either GRHL proteins as described above. Cells were incubated for 48 hours, then harvested for luciferase assay (FIG 16A) or total RNA extracted for qPCR analysis (FIG. 16B). M= Mock, G1= GRHL1-FL, G2=GRHL2-FL, G2-S=GRHL2-Spliced.

DETAILED DESCRIPTION OF INVENTION

The present disclosure, in some aspects, includes a method for modulating miR-122 expression in a cell. In some embodiments, the methods involve contacting a cell with an effective amount of a grainyhead-like transcriptional regulator (GRHL) modulating agent. In some embodiments, the GRHL modulating agent modulates grainyhead-like 1 (GRHL1), grainyhead-like 2 (GRHL2), and/or grainyhead-like 3 (GRHL3) transcriptional regulator. In other embodiments, the GRHL modulating agent modulates grainyhead-like 2 (GRHL2) transcriptional regulator, optionally spliced GRHL2. In another embodiment, the cell is a hepatocyte. In some embodiments, the cell is a parenchymal hepatocyte, non-parenchymal hepatocyte, sinusoidal endothelial cell, Kupffer cell, hepatic stellate cell, or intrahepatic lymphocyte. In another embodiment, the grainyhead-like (*e.g.*, GRHL2) modulating agent is a protein or a nucleic acid. In other embodiments, the grainyhead-like (*e.g.*, GRHL2) modulating agent is an inhibitory nucleic acid. In another embodiment, the inhibitory nucleic acid is selected from the group consisting of dsRNA, siRNA, shRNA, pri-miRNA, miRNA, and artificial miRNA (amiRNA). In some embodiments, the miRNA or amiRNA is a tough decoy (TUD) miRNA. In another embodiment, the nucleic acid is flanked by adeno-associated virus (AAV) inverted terminal repeats (ITRs). In some embodiments, the nucleic acid is encapsidated by one or more adeno-associated virus (AAV) capsid protein. In other embodiments, the one or more capsid protein is a liver-trophic capsid protein. In some embodiments, the one or more capsid protein is an AAV2, AAV3, AAV3b, AAV7, AAV8, or AAV9 capsid protein.

The present disclosure, in some aspects, includes a method for modulating hypoxia-inducible factor 1 α (HIF-1 α) expression in a liver cell of a subject having a liver-associated disease, the method comprising increasing expression of miR-122 in the cell. In some embodiments, the expression of miR-122 is increased by delivering to the cell a nucleic acid engineered to express miR-122. For example, in some embodiments, a nucleic acid

engineered to express miR-122 comprises a recombinant adeno-associated virus (rAAV) vector comprising a transgene encoding miR-122.

In some embodiments, the nucleic acid engineered to express miR-122 comprises a promoter (*e.g.* a promoter operably linked to a transgene encoding miR-122). A promoter
5 can be an inducible promoter, a constitutive promoter, a tissue-specific promoter (*e.g.* a liver-specific promoter, such as the human thyroxine binding globulin (TBG) promoter), or any suitable combination of the foregoing.

In some embodiments, the cell is a hepatocyte. In other embodiments, the hepatic cell is a parenchymal hepatocyte, non-parenchymal hepatocyte, sinusoidal endothelial cell,
10 Kupffer cell, hepatic stellate cell, or intrahepatic lymphocyte. In another embodiment, the hypoxia-inducible factor 1 α (HIF-1 α) modulating agent is a protein or a nucleic acid. In some embodiments, the hypoxia-inducible factor 1 α (HIF-1 α) modulating agent is an inhibitory nucleic acid. In another embodiment, the inhibitory nucleic acid is selected from the group consisting of dsRNA, siRNA, shRNA, pri-miRNA, miRNA, and artificial miRNA
15 (amiRNA). In some embodiments, the miRNA or amiRNA is a tough decoy (TUD) miRNA. In other embodiments, the nucleic acid is flanked by adeno-associated virus (AAV) inverted terminal repeats (ITRs). In some embodiments, the nucleic acid is encapsidated by one or more adeno-associated virus (AAV) capsid protein. In other embodiments, the one or more capsid protein is a liver-trophic capsid protein. In another embodiment, the one or more
20 capsid protein is an AAV2, AAV3, AAV3b, AAV7, AAV8, or AAV9 capsid protein.

The present disclosure, in some aspects, includes a method for treating a liver-associated disease, the method comprising: administering to a subject having or suspected of having a liver-associated disease an effective amount of a grainyhead-like (GRHL)
transcriptional regulator modulating agent or a nucleic acid engineered to express miR-122.

In some embodiments, the GRHL modulating agent modulates grainyhead-like 1 (GRHL1), grainyhead-like 2 (GRHL2), and/or grainyhead-like 3 (GRHL3) transcriptional regulator. In other embodiments, the GRHL modulating agent modulates grainyhead-like 2 (*e.g.*, GRHL2) transcriptional regulator. In another embodiment, the subject is a mammal, optionally a human. In some embodiments, the liver-associated disease is characterized by a decrease in
30 miR-122 expression relative to a subject not having the liver-associated disease. In another embodiment, the liver-associated disease is alcoholic liver disease (ALD), cirrhosis, hepatitis A, hepatitis B, hepatitis C, hepatocellular carcinoma (HCC), or fibrosis of the liver. In another embodiment, the grainyhead-like (*e.g.*, GRHL2) modulating agent increases miR-122 expression in the subject. In some embodiments, the grainyhead-like (*e.g.*, GRHL2)

modulating agent decreases miR-122 expression, or decreases HIF-1 α expression, in the subject. In another embodiment, the grainyhead-like (*e.g.*, GRHL2) modulating agent is a protein or a nucleic acid. In other embodiments, the nucleic acid is an inhibitory nucleic acid. In another embodiment, the inhibitory nucleic acid is selected from the group consisting of dsRNA, siRNA, shRNA, pri-miRNA, miRNA, and artificial miRNA (amiRNA). In some 5 embodiments, the miRNA or amiRNA is a tough decoy (TUD) miRNA. In another embodiment, the grainyhead-like (*e.g.*, GRHL2) modulating agent nucleic acid engineered to express miR-122 is administered to the subject in a recombinant adeno-associated virus (rAAV). In another embodiment, the rAAV comprises one or more AAV capsid protein. In 10 other embodiments, the one or more capsid protein is a liver-trophic capsid protein. In some embodiments, the one or more capsid protein is an AAV2, AAV3, AAV3b, AAV7, AAV8, or AAV9 capsid protein.

The present disclosure, in some aspects, includes a method for treating a liver-associated disease, the method comprising: administering to a subject having or suspected of 15 having a liver-associated disease an effective amount of a recombinant adeno-associated virus comprising a transgene encoding miR-122. In some embodiments, the subject is a mammal, optionally a human. In other embodiments, the liver-associated disease is alcoholic liver disease (ALD), cirrhosis, hepatitis A, hepatitis B, hepatitis C, hepatocellular carcinoma (HCC), or fibrosis of the liver. In other embodiments, the transgene encoding miR-122 20 comprises a sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2. In another embodiment, the rAAV comprises a liver-trophic capsid protein. In some embodiments, the capsid protein is an AAV2, AAV3, AAV3b, AAV7, AAV8, or AAV9 capsid protein.

Grainyhead-like (GRHL) Proteins

25 Grainyhead-like (GRHL) transcription factors have been observed to play regulatory roles during development, for example by acting as an activator and/or repressor of distinct target genes. The GRHL transcription factor family encompasses GRHL transcription factors GRHL1-3. For example, amino acid sequences of human GRHL1-3 are provided in Table 1.

30 Table 1. Human GRHL1-3.

Protein	No. of AA	GenBank Accession No.	UniProt ID	SEQ ID NO:
GRHL1	618	NP_937825.2	Q9NZI5	31

GRHL2	625	NP_079191.2	Q6ISB3	32
GRHL3	626	NP_067003.2	Q8TE85	33

GRHL1-3 are structurally similar, each containing an evolutionarily conserved CP2 DNA binding domain flanked by an N-terminal transactivation domain and a C-terminal DNA binding domain. In fact, an amino acid sequence comparison reveals that the human
 5 homologue of murine GRHL1 to be 94% identical at the amino acid level. Further, GRHL1 and GRHL2 share 90% sequence homology at the amino acid level. In general, each protein has a N-terminal transactivation domain, a linker region, and a C-terminal dimerization domain.

The GRHL modulating agent to be used in the methods described herein can be a
 10 molecule that modulates (*e.g.*, reduces or enhances) the expression level or biological activities of any one of GRHL1-3. In some embodiments, the term “GRHL modulating agent” refers to an agent that modulates GRHL (*e.g.*, GRHL1, GRHL2, or GRHL3) levels and/or activity (including but not limited to its ability to decrease miR-122 expression), *e.g.*, by at least 20%, 50%, 70%, 85%, 90%, 100%, 150%, 200%, 300%, or 500%, or by 10-fold,
 15 20-fold, 50-fold, 100-fold, 1000-fold, or 10⁴-fold.

As shown herein, GRHL inhibits the expression of miR-122, and GRHL and miR-122 levels may vary by cell type. In some embodiments, a hepatocyte refers to a fully or partially differentiated cell of hepatocyte lineage arising from endoderm. In some embodiments, a mature hepatocyte expresses detectable to relatively high levels of albumin. Accordingly, in
 20 some embodiments, albumin is a marker for of a mature hepatocyte. The term “biliary cells” refers to hepatic biliary cells which line the bile ducts.

In some embodiments, GRHL1 is expressed (*e.g.*, constitutively) in hepatocytes. In some embodiments, GRHL2 is predominantly expressed in biliary cells. In some
 25 embodiments, the expression level of GRHL is inversely proportional to miR-122. In some embodiments, miR-122 expression in biliary cells is low. In some embodiments, miR-122 expression is lower in biliary cells than miR-122 expression in hepatocytes. In some embodiments, miR-122 expression is lower in immature hepatocytes than miR-122 expression in mature hepatocytes.

30 *Recombinant AAVs*

In some aspects, the disclosure relates to delivery of a modulator (*e.g.*, grainyhead-like (GRHL) transcriptional regulator modulating agent) or a nucleic acid engineered to express miR-122 (*e.g.*, a rAAV vector comprising a transgene encoding miR-122, such as pri-miR-122). In some embodiments, a composition described by the disclosure is delivered to a cell using an isolated recombinant adeno-associated virus (rAAV).

As used herein with respect to AAVs, the term “isolated” refers to an AAV that has been artificially produced or obtained. Isolated AAVs may be produced using recombinant methods. Such AAVs are referred to herein as “recombinant AAVs”. Recombinant AAVs (rAAVs) preferably have tissue-specific targeting capabilities, such that a transgene of the rAAV will be delivered specifically to one or more predetermined tissue(s). The AAV capsid is an important element in determining these tissue-specific targeting capabilities. Thus, an rAAV having a capsid appropriate for the tissue being targeted can be selected. Methods for obtaining recombinant AAVs having a desired capsid protein are well known in the art. (See, for example, US 2003/0138772), the contents of which are incorporated herein by reference in their entirety). Typically the methods involve culturing a host cell which contains a nucleic acid sequence encoding an AAV capsid protein; a functional *rep* gene; a recombinant AAV vector composed of, AAV inverted terminal repeats (ITRs) and a transgene; and sufficient helper functions to permit packaging of the recombinant AAV vector into the AAV capsid proteins. In some embodiments, capsid proteins are structural proteins encoded by the cap gene of an AAV. AAVs comprise three capsid proteins, virion proteins 1 to 3 (named VP1, VP2 and VP3), all of which are transcribed from a single cap gene via alternative splicing. In some embodiments, the molecular weights of VP1, VP2 and VP3 are respectively about 87 kDa, about 72 kDa and about 62 kDa. In some embodiments, upon translation, capsid proteins form a spherical 60-mer protein shell around the viral genome. In some embodiments, the functions of the capsid proteins are to protect the viral genome, deliver the genome and interact with the host. In some aspects, capsid proteins deliver the viral genome to a host in a tissue specific manner.

The components to be cultured in the host cell to package a rAAV vector in an AAV capsid may be provided to the host cell in *trans*. Alternatively, any one or more of the required components (*e.g.*, recombinant AAV vector, *rep* sequences, *cap* sequences, and/or helper functions) may be provided by a stable host cell which has been engineered to contain one or more of the required components using methods known to those of skill in the art. Most suitably, such a stable host cell will contain the required component(s) under the control of an inducible promoter. However, the required component(s) may be under the control of a

constitutive promoter. Examples of suitable inducible and constitutive promoters are provided herein, in the discussion of regulatory elements suitable for use with the transgene. In still another alternative, a selected stable host cell may contain selected component(s) under the control of a constitutive promoter and other selected component(s) under the control of one or more inducible promoters. For example, a stable host cell may be generated which is derived from 293 cells (which contain E1 helper functions under the control of a constitutive promoter), but which contain the rep and/or cap proteins under the control of inducible promoters. Still other stable host cells may be generated by one of skill in the art. The recombinant AAV vector, rep sequences, cap sequences, and helper functions required for producing the rAAV of the disclosure may be delivered to the packaging host cell using any appropriate genetic element (vector). The selected genetic element may be delivered by any suitable method, including those described herein.

The methods used to construct any embodiment of this disclosure are known to those with skill in nucleic acid manipulation and include genetic engineering, recombinant engineering, and synthetic techniques. See, *e.g.*, Sambrook et al, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press, Cold Spring Harbor, N.Y. Similarly, methods of generating rAAV virions are well known and the selection of a suitable method is not a limitation on the present disclosure. See, *e.g.*, K. Fisher et al, *J. Virol.*, 70:520-532 (1993) and U.S. Pat. No. 5,478,745.

Administration

In some embodiments, a modulator (*e.g.*, grainyhead-like (GRHL) transcriptional regulator modulating agent or a nucleic acid engineered to express miR-122 (*e.g.*, a rAAV vector comprising a transgene encoding miR-122, such as pri-miR-122) is delivered to a cell (*e.g.*, administered to a patient in need thereof) as a recombinant adeno-associated virus (rAAV). The component can be fused to the capsid protein (*e.g.*, VP2) of the rAAV, encoded as a transgene in an rAAV vector, or a combination of the foregoing.

rAAVs may be delivered to a subject in compositions according to any appropriate methods known in the art. The rAAV, preferably suspended in a physiologically compatible carrier (*e.g.*, in a composition), may be administered to a subject, *e.g.*, host animal, such as a human, mouse, rat, cat, dog, sheep, rabbit, horse, cow, goat, pig, guinea pig, hamster, chicken, turkey, or a non-human primate (*e.g.*, Macaque). In some embodiments, a host animal is a human. In some embodiments a host animal does not include a human.

Delivery of the rAAVs to a mammalian subject may be by, for example, intramuscular injection or by administration into the bloodstream of the mammalian subject. Administration into the bloodstream may be by injection into a vein, an artery, or any other vascular conduit. In some embodiments, the rAAVs are administered into the bloodstream by way of isolated limb perfusion, a technique well known in the surgical arts, the method essentially enabling the artisan to isolate a limb from the systemic circulation prior to administration of the rAAV virions. A variant of the isolated limb perfusion technique, described in U.S. Pat. No. 6,177,403, can also be employed by the skilled artisan to administer the virions into the vasculature of an isolated limb to potentially enhance transduction into muscle cells or tissue. Moreover, in certain instances, it may be desirable to deliver the virions to the liver of a subject (*e.g.*, deliver a transgene using a rAAV having a liver-trophic AAV capsid protein).

An effective amount of an rAAV is an amount sufficient to target infect an animal, target a desired tissue. In some embodiments, an effective amount of an rAAV is an amount sufficient to produce a stable somatic transgenic animal model. The effective amount will depend primarily on factors such as the species, age, weight, health of the subject, and the tissue to be targeted, and may thus vary among animal and tissue. For example, an effective amount of the rAAV is generally in the range of from about 1 ml to about 100 ml of solution containing from about 10^9 to 10^{16} genome copies. In some cases, a dosage between about 10^{11} to 10^{13} rAAV genome copies is appropriate. In certain embodiments, 10^{12} or 10^{13} rAAV genome copies is effective to target heart, liver, and pancreas tissues. In some cases, stable transgenic animals are produced by multiple doses of an rAAV.

GRHL Modulating Agents

Grainyhead-like transcriptional regulator (GRHL) modulating agents can be used in methods described herein. In some embodiments, a GRHL modulating agent (*e.g.*, a small molecule inhibitor or a peptide inhibitor) inhibits binding of GRHL to a miR-122 promoter or other regulatory element thereby inhibiting expressing of miR-122. In some embodiments the GRHL modulating agent inhibits expression of GRHL (*e.g.*, an interfering RNA that targets GRHL mRNA).

In other embodiments, the GRHL modulating agent comprises at least one GRHL inhibitory compound. As used herein, "GRHL inhibitory compound" refers to a compound that directly or indirectly reduces, inhibits, neutralizes, or abolishes GRHL biological

activity. In some embodiments, a GRHL inhibitory compound exhibits any one or more of the following characteristics: (a) binds to GRHL mRNA or protein and inhibits its biological activity and/or downstream pathways mediated by GRHL; (b) increases expression of miR-122; (c) decreases expression of HIF-1 α ; and/or (d) reduces liver damage, steatosis, and/or inflammation. One skilled in the art can prepare other small molecules inhibitory compounds.

In some embodiments, the GRHL inhibitory compounds described herein are small molecules, which can have a molecular weight of about any of 100 to 20,000 Daltons, 500 to 15,000 Daltons, or 1000 to 10,000 Daltons. Libraries of small molecules are commercially available. The small molecules can be administered using any means known in the art, including inhalation, intraperitoneally, intravenously, intramuscularly, subcutaneously, intrathecally, intraventricularly, orally, enterally, parenterally, intranasally, or dermally. In general, when the GRHL modulating agent according to the invention is a small molecule, it will be administered at the rate of 0.1 to 300 mg/kg of the weight of the patient divided into one to three or more doses. For an adult patient of normal weight, doses ranging from 1 mg to 5 g per dose can be administered.

The small molecules referred to herein can be obtained from compound libraries. The libraries can be spatially addressable parallel solid phase or solution phase libraries. See, e.g., Zuckermann et al. J. Med. Chem. 37, 2678-2685, 1994; and Lam Anticancer Drug Des. 12:145, 1997. Methods for the synthesis of compound libraries are well known in the art, e.g., DeWitt et al. PNAS USA 90:6909, 1993; Erb et al. PNAS USA 91:11422, 1994; Zuckermann et al. J. Med. Chem. 37:2678, 1994; Cho et al. Science 261:1303, 1993; Carrell et al. Angew Chem. Int. Ed. Engl. 33:2059, 1994; Carell et al. Angew Chem. Int. Ed. Engl. 33:2061, 1994; and Gallop et al. J. Med. Chem. 37:1233, 1994. Libraries of compounds may be presented in solution (e.g., Houghten Biotechniques 13:412-421, 1992), or on beads (Lam Nature 354:82-84, 1991), chips (Fodor Nature 364:555-556, 1993), bacteria (U.S. Patent No. 5,223,409), spores (U.S. Patent No. 5,223,409), plasmids (Cull et al. PNAS USA 89:1865-1869, 1992), or phages (Scott and Smith Science 249:386-390, 1990; Devlin Science 249:404-406, 1990; Cwirla et al. PNAS USA 87:6378-6382, 1990; Felici J. Mol. Biol. 222:301-310, 1991; and U.S. Patent No. 5,223,409).

Alternatively, the GRHL modulating agent may be an agent that decreases GRHL expression, for example, morpholino oligonucleotides, small interfering RNA (siRNA or RNAi), antisense nucleic acids, or ribozymes (e.g., that specifically target GRHL mRNA and

inhibit its translation and/or brings about its degradation). RNA interference (RNAi) is a process in which a dsRNA directs homologous sequence-specific degradation of messenger RNA. In mammalian cells, RNAi can be triggered by 21-nucleotide duplexes of small interfering RNA (siRNA) without activating the host interferon response. The dsRNA used
5 in the methods disclosed herein can be a siRNA (containing two separate and complementary RNA chains) or a short hairpin RNA (*i.e.*, a RNA chain forming a tight hairpin structure), both of which can be designed based on the sequence of the target gene (*e.g.*, a mRNA sequence encoding an amino acid sequence as set forth in SEQ ID NO: 31-33).

In some embodiments, the GRHL modulating agent may be a nucleic acid aptamer
10 that binds to GRHL and inhibits its activity (anti-GRHL aptamers), thereby increasing levels of miR-122. A nucleic acid aptamer as used herein refers to a nucleic acid molecule (DNA or RNA) having a binding activity for a particular target molecule (*e.g.*, GRHL). The aptamer can inhibit the activity of a particular target molecule by binding to the particular target molecule. The anti-GRHL aptamer of the present disclosure, in linear or circular form, may
15 be an RNA, a DNA (*e.g.*, a single-stranded DNA), a modified nucleic acid, or a mixture thereof. The anti-GRHL aptamers may be non-naturally occurring molecules (*e.g.*, containing a nucleotide sequence not existing in native genes or containing modified nucleotides not existing in nature). Alternatively or in addition, the anti-GRHL aptamers may contain a nucleotide sequence that encodes a functional peptide.

In some embodiments, the GRHL modulating agent increases expression of GRHL
20 (*e.g.*, nucleic acids encoding GRHL). Plasmid vectors for expression of GRHL, or a fragment thereof, include conventional control elements which are operably linked to the nucleic acids encoding GRHL in a manner which permits its transcription, translation and/or expression in a cell transfected with the plasmid vector. As used herein, “operably linked”
25 sequences include both expression control sequences that are contiguous with the gene of interest and expression control sequences that act in trans or at a distance to control the gene of interest. However, in some embodiments, the GRHL modulating agent is a synthetic GRHL mRNA that may be delivered to cells to increase expression of a GRHL protein.

In some embodiments, the GRHL modulating agent increases expression of a mutated
30 GRHL. In some embodiments, the mutated GRHL comprises one or more mutations in the DNA binding domain. In some embodiments, the mutated GRHL comprises one or more mutations in the transactivation domain. In some embodiments, the one or more mutations is at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at

least eight, at least nine, at least ten, at least fifteen, at least twenty, or at least twenty five mutations in the DNA binding domain and/or the transactivation domain.

Expression control sequences include appropriate transcription initiation, termination, promoter and enhancer sequences; efficient RNA processing signals such as splicing and polyadenylation (polyA) signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (*i.e.*, Kozak consensus sequence); sequences that enhance protein stability; and when desired, sequences that enhance secretion of the encoded product. A great number of expression control sequences, including promoters which are native, constitutive, inducible and/or tissue-specific, are known in the art and may be utilized.

As used herein, a nucleic acid sequence (*e.g.*, coding sequence) and regulatory sequences are said to be “operably” linked when they are covalently linked in such a way as to place the expression or transcription of the nucleic acid sequence under the influence or control of the regulatory sequences. If it is desired that the nucleic acid sequences be translated into a functional protein, two DNA sequences are said to be operably linked if induction of a promoter in the 5’ regulatory sequences results in the transcription of the coding sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the coding sequences, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a promoter region would be operably linked to a nucleic acid sequence if the promoter region were capable of effecting transcription of that DNA sequence such that the resulting transcript might be translated into the desired protein or polypeptide. Similarly two or more coding regions are operably linked when they are linked in such a way that their transcription from a common promoter results in the expression of two or more proteins having been translated in frame. In some embodiments, operably linked coding sequences yield a fusion protein. In some embodiments, operably linked coding sequences yield a functional RNA (*e.g.*, gRNA).

Optionally, a nucleic acid molecule to be used in the method described herein (*e.g.*, an antisense nucleic acid, a small interfering RNA, or a microRNA) as described above contains non-naturally-occurring nucleobases, sugars, or covalent internucleoside linkages (backbones). Such a modified oligonucleotide confers desirable properties such as enhanced cellular uptake, improved affinity to the target nucleic acid, and increased *in vivo* stability.

In one example, the nucleic acid has a modified backbone, including those that retain a phosphorus atom (see, *e.g.*, U.S. Patents 3,687,808; 4,469,863; 5,321,131; 5,399,676; and 5,625,050) and those that do not have a phosphorus atom (see, *e.g.*, US Patents 5,034,506;

5,166,315; and 5,792,608). Examples of phosphorus-containing modified backbones include, but are not limited to, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkyl-phosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates, 5'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, selenophosphates and boranophosphates having 3'-5' linkages, or 2'-5' linkages. Such backbones also include those having inverted polarity, i.e., 3' to 3', 5' to 5' or 2' to 2' linkage. Modified backbones that do not include a phosphorus atom are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. Such backbones include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; riboacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH₂ component parts.

In another example, the nucleic acid used in the disclosed methods includes one or more substituted sugar moieties. Such substituted sugar moieties can include one of the following groups at their 2' position: OH; F; O-alkyl, S-alkyl, N-alkyl, O-alkenyl, S-alkenyl, N-alkenyl; O-alkynyl, S-alkynyl, N-alkynyl, and O-alkyl-O-alkyl. In these groups, the alkyl, alkenyl and alkynyl can be substituted or unsubstituted C₁ to C₁₀ alkyl or C₂ to C₁₀ alkenyl and alkynyl. They may also include at their 2' position heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide. Preferred substituted sugar moieties include those having 2'-methoxyethoxy, 2'-dimethylaminoethoxy, and 2'-dimethylaminoethoxyethoxy. See Martin et al., *Helv. Chim. Acta*, 1995, 78, 486-504.

In yet another example, the nucleic acid includes one or more modified native nucleobases (*i.e.*, adenine, guanine, thymine, cytosine and uracil). Modified nucleobases include those described in U.S. Patent 3,687,808, *The Concise Encyclopedia Of Polymer Science And Engineering*, pages 858-859, Kroschwitz, J. I., ed. John Wiley & Sons, 1990, Englisch et al., *Angewandte Chemie, International Edition*, 1991, 30, 613, and Sanghvi, Y.

S., Chapter 15, Antisense Research and Applications, pages 289-302, CRC Press, 1993.

Certain of these nucleobases are particularly useful for increasing the binding affinity of the antisense oligonucleotide to its target nucleic acid. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines (*e.g.*, 2-aminopropyl-adenine, 5-propynyluracil and 5-propynylcytosine). See Sanghvi, et al., eds., Antisense Research and Applications, CRC Press, Boca Raton, 1993, pp. 276-278).

Any of the nucleic acids can be synthesized by methods known in the art. See, *e.g.*, Caruthers et al., 1992, Methods in Enzymology 211, 3-19, Wincott et al., 1995, Nucleic Acids Res. 23, 2677-2684, Wincott et al., 1997, Methods Mol. Bio. 74, 59, Brennan et al., 1998, Biotechnol Bioeng., 61, 33-45, and Brennan, U.S. Pat. No. 6,001,311. It can also be transcribed from an expression vector and isolated using standard techniques.

Methods of Use

In some embodiments, to practice methods disclosed herein, an effective amount of a GRHL modulating agent, a HIF-1 α modulating agent, or a transgene encoding miR-122 described herein can be administered to a subject (*e.g.*, a human) in need of the treatment via a suitable route (*e.g.*, intravenous administration).

In some embodiments, the subject to be treated by the methods described herein can be a human patient having, suspected of having, or at risk for a liver associated disease. Examples of a liver associated disease include, but are not limited to, alcoholic liver disease (ALD), cirrhosis, hepatitis A, hepatitis B, hepatitis C, hepatocellular carcinoma (HCC), liver cancer, and fibrosis of the liver. Examples of liver cancer include, but are not limited to, hepatocellular carcinoma (HCC), fibrolamellar HCC, cholangiocarcinoma, angiosarcoma, or secondary liver cancer.

In some embodiments, the subject to be treated by the methods described herein can be a human patient having, suspected of having, or at risk for cancer. Examples of cancer include, but are not limited to, squamous cell carcinoma of the skin, breast cancer, gastric cancer, hepatocellular carcinoma, colorectal cancer, clear cell renal cell carcinoma, neuroblastoma, prostate cancer, and cervical cancer.

In some embodiments, the subject to be treated by the methods described herein can be a mammal, more preferably a human. Mammals include, but are not limited to, farm animals, sport animals, pets, primates, horses, dogs, cats, mice and rats. A human subject who needs the treatment may be a human patient having, at risk for, or suspected of having a

liver-associated disease (*e.g.*, ALD). In some embodiments, a subject having a liver-associated disease can be identified by routine medical examination, *e.g.*, laboratory tests, biopsy, CT scans, or ultrasounds. In some embodiments, a subject suspected of having a liver-associated disease might show one or more symptoms of the disorder, *e.g.*, unexplained weight loss, fever, fatigue, pain, nausea, and/or jaundice. In some embodiments, a subject at risk for a liver-associated disease can be a subject having one or more of the risk factors for that disorder. For example, risk factors associated with a liver-associated disease include (a) viral infection (*e.g.*, hepatitis virus infection), (b) age, (c) family history, (d) heavy alcohol consumption, (e) drug use, and (f) iron overload.

“An effective amount” as used herein refers to the amount of each active agent required to confer therapeutic effect on the subject, either alone or in combination with one or more other active agents. Effective amounts vary, as recognized by those skilled in the art, depending on the particular condition being treated, the severity of the condition, the individual patient parameters including age, physical condition, size, gender and weight, the duration of the treatment, the nature of concurrent therapy (if any), the specific route of administration and like factors within the knowledge and expertise of the health practitioner. These factors are well known to those of ordinary skill in the art and can be addressed with no more than routine experimentation. It is generally preferred that a maximum dose of the individual components or combinations thereof be used, that is, the highest safe dose according to sound medical judgment. It will be understood by those of ordinary skill in the art, however, that a patient may insist upon a lower dose or tolerable dose for medical reasons, psychological reasons or for virtually any other reasons.

Empirical considerations, such as the half-life, generally will contribute to the determination of the dosage. Frequency of administration may be determined and adjusted over the course of therapy, and is generally, but not necessarily, based on treatment and/or suppression and/or amelioration and/or delay of a liver-associated disease. Alternatively, sustained continuous release formulations of a GRHL modulating agent, a HIF-1 α modulating agent, or a transgene encoding miR-122 may be appropriate. Various formulations and devices for achieving sustained release are known in the art.

In one example, dosages for a GRHL modulating agent, a HIF-1 α modulating agent, or a transgene encoding miR-122 as described herein may be determined empirically in individuals who have been given one or more administration(s) of GRHL modulating agent, HIF-1 α modulating agent, or transgene encoding miR-122. Individuals are given incremental

dosages of the GRHL modulating agent, the HIF-1 α modulating agent, or the transgene encoding miR-122. To assess efficacy of the agents, an indicator of a liver-associated disease (miR-122 expression levels) can be followed.

As used herein, the term "treating" refers to the application or administration of a composition including one or more active agents to a subject, who has a liver-associated disease, a symptom of a liver-associated disease, or a predisposition toward a liver-associated disease, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve, or affect the disorder, the symptom of the disease, or the predisposition toward a liver-associated disease.

Alleviating a liver-associated disease includes delaying the development or progression of the disease, or reducing disease severity. Alleviating the disease does not necessarily require curative results. As used herein, "delaying" the development of a disease (such as ALD) means to defer, hinder, slow, retard, stabilize, and/or postpone progression of the disease. This delay can be of varying lengths of time, depending on the history of the disease and/or individuals being treated. A method that "delays" or alleviates the development of a disease, or delays the onset of the disease, is a method that reduces probability of developing one or more symptoms of the disease in a given time frame and/or reduces extent of the symptoms in a given time frame, when compared to not using the method. Such comparisons are typically based on clinical studies, using a number of subjects sufficient to give a statistically significant result.

"Development" or "progression" of a disease means initial manifestations and/or ensuing progression of the disease. Development of the disease can be detectable and assessed using standard clinical techniques as well known in the art. However, development also refers to progression that may be undetectable. For purpose of this disclosure, development or progression refers to the biological course of the symptoms. "Development" includes occurrence, recurrence, and onset. As used herein "onset" or "occurrence" of a liver-associated disease includes initial onset and/or recurrence.

In some embodiments, it is also apparent that a therapeutic effect of a GRHL modulating agent, a HIF-1 α modulating agent, or a transgene encoding miR-122 as described herein may be to stimulate hepatocyte growth. Thus, in some embodiments, the therapeutic effect is improvement of liver function. In some embodiments, the therapeutic effect is replication of hepatocytes, biliary epithelial cells, and/or sinusoidal endothelial cells. Alternatively or in addition, the therapeutic effect is liver regeneration. In some

embodiments, liver regeneration comprises regeneration of liver tissue following a liver resection. In some embodiments, liver regeneration comprises regeneration of liver tissue following a liver transplantation.

In other aspects, the methods described herein are based, at least in part, on the identification of biomarkers that were found to be differentially present in liver-associated disease (*e.g.*, alcoholic liver disease) as compared to a non-disease. As used herein, the term “biomarker” or “biomarker set” indicative of a specific population of cells (*e.g.*, hepatocytes) refers to a biological molecule (*e.g.*, GRHL) or set of such biological molecules that are present at a level in that specific population of cells that deviates from a level of the same molecule in a different population of cells. For example, a biomarker that is indicative of a liver-associated disease may have an elevated level or a reduced level in liver-associated disease as relative to the level of the same marker in non-liver-associated-disease. The liver-associated disease biomarkers described herein may have a level in liver-associated disease that deviate from (enhanced or reduced) the level of the same marker in non-liver-associated disease by at least 10% (*e.g.*, 15%, 30%, 50%, 75%, 100%, 2-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold or more). Such biomarker/biomarker sets may be used in both diagnostic/prognostic applications and non-clinical applications (*e.g.*, for research purposes).

EXAMPLE

Inhibition Of MiRNA-122 Expression by Grainyhead-Like 2 Promotes Alcoholic Liver Disease through HIF-1 α Activation in Hepatocytes

Chronic alcohol consumption accounts for nearly 50% of liver-related death in the United States, however, no effective therapies exist for patients. While early steatosis in ALD is reversible, chronic, excessive alcohol consumption leads to cirrhosis and it is the single greatest cause of hepatocellular cancer (HCC). Acute alcoholic hepatitis has a 30%-50% 30-day mortality and the standard of care with steroids has limited benefits and significant side effects. Thus, identification of novel therapeutic targets is a major clinical need in ALD.

Alcoholic liver disease is characterized by liver steatosis, inflammation and progressive fibrosis with prolonged alcohol use. Alcohol-triggered hepatocyte steatosis and cell death results in the activation and infiltration of immune cells within the liver leading to advanced hepatic injury. The subsequent release of inflammatory cytokines causes further hepatocyte cell death resulting in perpetuation of liver injury.

Hepatic microRNAs (miRNAs) have crucial roles in maintaining liver homeostasis,

mitochondrial function, and regulating oncogenesis. miR-122 constitutes 70% of all miRNAs in mature hepatocytes, or approximately 130,000 copies per cell, with negligible expression in other cells and tissues. Germ line deletions of miR-122 display steatosis at birth, spontaneous progression to fibrosis, and HCC. In humans, liver miR-122 expression inversely correlates with HCC survival and metastasis, while miR-122 inhibition reduces HCV viremia, serum triglycerides, and cholesterol.

Encoded on chromosome 18 in mice and humans, miR-122 is transcribed as a ~4.7 kb noncoding pri-miRNA transcript by RNA polymerase II which is then rapidly processed into a 66-nucleotide (nt) pre-miR-122 by Drosha. Subsequently, the pre-miRNA is shuttled into the cytoplasm where it is processed into its mature 23-nt form. In the liver, its abundance and specificity to hepatocytes is regulated at the transcriptional level by a host of liver-specific transcription factors including hepatocyte nuclear factors (HNFs) 1 α , 3 β , 4 α , and 6 α . While factors which maintain the high level of expression of miR-122 in the healthy liver have been well studied, little is known about the epigenetic regulation of its expression in disease states.

In this example, effects alcohol use on modulation of miR-122 in the liver was examined. The significant reduction of miR-122 expression in hepatocytes due to epigenetic inhibition of transcription by chronic alcohol-induced grainyhead family of transcription factors is demonstrated. Data indicate that reduction of miR-122 regulates the pathogenesis of ALD through its primary target, HIF-1 α , in hepatocytes. Therapeutic benefit of miR-122 restoration in hepatocytes is demonstrated using viral vector-mediated gene therapy.

miR-122 expression is decreased in livers and hepatocytes after chronic alcohol use in humans and mice

Investigation of diseased livers revealed that miR-122 expression was significantly reduced (by 2-fold) in patients with alcoholic cirrhosis when compared to HCV cirrhosis or healthy controls, (FIG. 1A, Table 1) suggesting that chronic alcohol may promote liver injury by inhibiting miR-122. To further dissect the role of miR-122, a chronic alcohol feeding model of ALD in mice was used. miR-122 expression was significantly reduced in the livers of alcohol-fed mice compared to pair-fed controls (FIG. 1B) and the extent of reduction was equivalent to that seen in human patients.

To determine the cell specificity of the miR-122 reduction, primary hepatocytes and liver mononuclear cells (LMNCs) were isolated. miR-122 was selectively decreased in hepatocytes and not in CD45+ LMNCs from alcohol-fed mice (FIG. 1C) when compared to

pair-fed controls. This data indicates that alcohol-induced changes in miR-122 in the total liver are hepatocyte-specific.

miR-122 reduction in hepatocytes mimics alcoholic liver disease

5 Given the miR-122 reduction observed after chronic alcohol in murine hepatocytes, the ability of inhibition of miR-122 *in vivo* to mimic features of alcoholic liver disease was investigated. To inhibit miR-122 *in vivo*, a self-complimentary adeno-associated virus 8 (scAAV8) vector system expressing an anti-miR-122 Tough Decoy (TuD) was produced. This scAAV8 has tropism for hepatocytes and maintains sustained inhibition of miR-122 in
10 murine livers. Wild type (WT) mice were treated with scAAV8-scrambled (Scr) or scAAV8-anti-miR-122-TuD (miR-122 TuD) 2-weeks prior to initiation of the chronic alcohol feeding to permit full vector expression (FIG. 10A).

 In WT mice, scAAV8 miR-122 TuD achieved a robust and sustained knockdown of miR-122 in both pair-fed and alcohol-fed mice (FIG. 1D). Interestingly, in addition to the
15 scAAV8 miR-122 TuD-induced reduction, liver miR-122 levels were further decreased by ethanol feeding compared to pair-fed TuD treated mice (FIG. 1D). TuD-mediated inhibition of miR-122 alone resulted in a significant increase in serum ALT (FIG. 1E) and hepatic steatosis (FIG. 1F) that was equivalent to that induced by the alcohol-diet. The combination of alcohol plus miR-122-TuD treatment resulted in a synergistic effect further increasing
20 serum ALT (FIG. 1E) hepatic lipid accumulation (FIG. 1F) and this correlated with decreasing miR-122 expression in hepatocytes (FIG. 1D).

miR-122 directly regulates HIF-1 α in hepatocytes

 To assess mechanism by which miR-122 decrease could mediate liver injury and
25 steatosis, potential miR-122 targets that may contribute to the development of ALD were examined. Using the TargetScan algorithm, based on seed recognition, HIF-1 α was identified as a putative target of miR-122. Generally, alcohol increases HIF-1 α expression in hepatocytes and hepatocyte-specific HIF-1 α knockout mice (HIF1 $\alpha^{\text{hep-/-}}$) were protected from chronic alcohol, while transgenic mice, expressing a constitutively active form of HIF-1 α
30 (HIF1dPA) in hepatocytes, had augmented alcohol-induced liver injury. However, a direct relationship between miR-122 and HIF-1 α is yet to be explored. This analysis of the livers of alcoholic cirrhosis patients and hepatocytes of alcohol-fed mice revealed an increase of HIF-1 α mRNA that showed a significant inverse correlation with miR-122 expression (FIGs. 2A-2B; $p=0.0052$, $r^2=0.3770$ and $p=0.0094$, $r^2=0.3710$ respectively). This correlation indicated

that HIF-1 α regulation by miR-122 in hepatocytes may be a key element in the pathogenesis of ALD.

To establish that miR-122 directly regulates HIF-1 α through canonical miRNA pathways, a plasmid containing the HIF-1 α 3'UTR-luciferase reporter (HIF-3'luc, Origene) was cotransfected with scrambled or miR-122 mimic into HEK293T cells. The miR-122 mimic strongly repressed HIF-3'luc activity in a dose-dependent manner (FIG. 2C). As further evidence of the miR-122/HIF-1 α regulatory pathway, it was found that transfection of a miR-122 mimic or an inhibitor into primary murine hepatocytes results in decreased or increased HIF-1 α mRNA, respectively (FIGs. 9A-9B). These results confirmed that miR-122 directly inhibits HIF-1 α expression in hepatocytes.

miR-122 regulates HIF-1 α in vivo

Alcohol and knockdown of miR-122 in the livers of WT mice increased HIF-1 α mRNA individually and additively (FIG. 2D). To confirm that the increase in HIF-1 α mRNA represents increased transcriptional activity, an EMSA using a HIF-1 α consensus binding oligonucleotide was performed on hepatocyte nuclear extracts. Results indicate that TuD-mediated inhibition of miR-122 resulted in increased HIF-1 α DNA binding at baseline, equivalent to alcohol-feeding alone (FIG. 2D). Furthermore, the combination of alcohol and miR-122-TuD-inhibition yielded in a synergistic increase of HIF-1 α mRNA (FIG. 2D) and DNA-binding activity suggesting that alcohol directly and via miR-122 regulates HIF-1 α (FIG. 2D). HIF-1 α has numerous target genes and of those PPAR γ is important in affecting liver steatosis. Indeed, it was found that the increase in HIF-1 α activity also translated to an increase in PPAR γ expression (FIG. 2E), a direct target of HIF-1 α activation and a key factor in driving steatosis.

Hepatocyte-specific knockout of HIF-1 α protects from liver injury, steatosis, inflammation, and fibrosis induced by alcohol or miR-122 reduction

Based on the discovery that miR-122 is decreased by alcohol and that miR-122 inhibits HIF-1 α in hepatocytes, the ability of miR-122 to regulate HIF-1 α *in vivo* was investigated. It was examined whether mice with a hepatocyte-specific knockout of HIF-1 α (HIF1 $\alpha^{\text{hep-/-}}$) are protected from the miR-122-TuD and/or alcohol-induced liver injury.

It was found that in contrast to WT mice, HIF1 $\alpha^{\text{hep-/-}}$ mice were protected from liver injury (FIG. 3A) and steatosis (FIGs. 3B-3D) whether induced by alcohol or miR-122 inhibition alone, and their combination. Furthermore, HIF1 $\alpha^{\text{hep-/-}}$ also displayed no increase

in PPAR γ (FIG. 3E) associated with the knockdown of miR-122 and alcohol in WT mice. These data suggested first, that the loss of miR-122 in hepatocytes directly triggers an increase of HIF-1 α , resulting in steatosis and hepatocyte injury in the liver. Second, alcohol and exogenous miR-122 inhibition synergistically decrease in miR-122 and induce HIF-1 α , and subsequently PPAR γ .

Analysis of H&E sections and qPCR evaluation of immune cell markers revealed increased macrophage infiltration, CD68 and F4/80 (FIG. 3B, FIG. 4A, FIGs. 10C-10D) in anti-miR-122 TuD-treated, or alcohol-fed mice with an even greater increase in mice treated with both TuD and alcohol. Increased levels of IL-1 β and MCP-1 protein (FIG. 4A, FIGs. 10E-10F) were also found in the livers of alcohol and miR-122 TuD-treated mice. HIF1 $\alpha^{\text{hep-/-}}$ mice treated with either miR-122 inhibition or chronic alcohol showed a reduction in inflammatory cell infiltration and activation compared to WT mice. (FIG. 4A, FIG. 3B, FIGs. 10C-10F), indicating that in addition to steatosis, liver inflammation induced by miR-122 decrease is also attenuated by hepatocyte-specific HIF-1 α deficiency.

The development of fibrosis indicates progression of ALD as a result of sustained hepatocyte injury, inflammation, and stellate cell activation. Increases in fibrosis markers were found after alcohol feeding indicated by Sirius Red staining (FIG. 4B) and expression of pro-collagen-1 α and Acta2 (FIG. 4C). Furthermore, the highest expression of pro-collagen-1 α and Acta2 (FIG. 4C) expression, and Sirius Red staining was found in miR-122 TuD mice treated with alcohol, compared to pair-fed controls (FIG. 3B). The increase in fibrosis in the miR-122 TuD+Et group was abrogated in the HIF1 $\alpha^{\text{hep-/-}}$ mice (FIGs. 3B-3C). Together, these data indicate that the increased pro-inflammatory and pro-fibrotic state are secondary to HIF-1 α -mediated hepatocyte injury due to the reduction of miR-122.

Therapeutic restoration of miR-122 in hepatocytes rescues mice from alcohol-induced liver injury in vivo

To assess the therapeutic potential of miR-122 restoration on the pathogenesis of alcoholic liver disease, an scAAV8 vector expressing miR-122 (miR-122-OX) and a scrambled (scr) were produced. In a preliminary experiment, it was established that wild-type alcohol-fed mice develop significant liver injury by week 2 of the 5-week alcohol feeding (FIG. 11A). It was also determined that scAAV8 miR-122-OX construct requires 3 weeks for full expression in the liver (FIG. 11B). Therefore, pair-fed and alcohol-fed mice were treated with 6×10^{11} viral particles containing Scr or miR-122-OX construct via tail-vein injection on week 2 of a 5-week alcohol feeding model (FIG. 11C).

Treatment with the scAAV8-miR-122-OX effectively increased mature miR-122 levels in the livers of pair-fed and alcohol-treated mice (FIG. 5A). Overexpression of miR-122 in hepatocytes resulted in dramatic reductions in alcohol-induced increases in serum ALT (FIG. 5B), and steatosis indicated by histology and liver triglyceride levels (FIG. 5C).

Consistent with *in vitro* data (FIG. 9A-9B), *in vivo* restoration of miR-122 in hepatocytes prevented the alcohol-induced increase in HIF-1 α mRNA, DNA binding activity, and the HIF-1 α target gene driving lipogenesis, PPAR γ (FIGs. 5D-5E). Furthermore, miR-122-OX treatment prevented induction of inflammatory cytokines in ALD including MCP1 and IL-1 β at the protein (FIG. 5E) and mRNA levels (FIGs. 5D-5F). Overall, these data demonstrate that restoration of miR-122 in hepatocytes can suppress the pathogenic features of ALD via inhibition of HIF-1 α *in vivo* and indicates that hepatocyte-specific miR-122 delivery could be a therapeutic consideration in ALD.

Alcohol inhibits miR-122 transcription via alternate splicing of grainyhead-like 2 transcription factor

MicroRNAs are encoded by their own genes and regulated transcriptionally. Surprisingly, both PF and Et mice treated with scAAV8-miR-122-OX achieved similar expression levels of mature miR-122 (FIG. 5A). It was observed that alcohol administration could reduce miR-122 levels beyond the reduction achieved by the miR-122TuD in WT and HIF1 $\alpha^{\text{hep-/-}}$ mice (FIG. 10B). Utilizing TaqMan probes specific for the endogenous miR-122 primary transcript (pri-miR-122), it was found that alcohol reduces pri-miR-122 expression, not only mature miR-122, expression was decreased in livers of in human alcoholic cirrhosis patients (approximately 2-fold) while there was no change in pri-miR-122 in patients with HCV cirrhosis (FIG. 6A). Livers of alcohol-fed mice, and specifically, isolated hepatocytes also showed a significant reduction in pri-miR-122 expression (FIG. 6B) similar to the reduction of mature miR-122 (FIGs. 1A-1B) suggesting transcriptional regulation. Of note, it was found reduced pri-miR-122 expression in hepatocytes of mice treated with either miR-122-TuD, or miR-122-OX, as well as HIF1 $\alpha^{\text{hep-/-}}$ (FIG. 6C) indicating that the effect of chronic alcohol on miR-122 transcription is independent of liver injury, or mature miR-122 levels.

The high baseline level of miR-122 in hepatocytes is maintained by transcription factors including HNF4 and HNF6. However, data indicate that none of these transcription factors showed changes in the livers of alcohol-fed mice compared to control mice (Figs. 12A-12C). Grainyhead like-2 (GRHL2), a homolog of the drosophila grainyhead transcriptional regulator, was investigated.

Using *in silico* analysis, a conserved grainyhead dimer binding site approximately 300 bps upstream of the miR-122 transcription start site (TSS) was identified, (FIG. 12D).

Chromatin immunoprecipitation-qPCR was performed on HUH-7 cells and confirmed the putative GRHL binding site in the miR-122 promoter (FIG. 6D). Total liver extracts from

5 alcohol-fed mice showed a modest, but statistically not statistically significant increase in GRHL2 mRNA expression (FIG. 6E). However, robust increases in GRHL2 expression were observed in the livers of alcoholic cirrhosis patients (FIG. 5F) when compared to healthy controls or livers with HCV cirrhosis. Furthermore, this 18-fold increase in GRHL2 demonstrated a significant inverse correlation with miR-122 expression (FIG. 6F, $r^2=0.6803$,
10 $P<0.0001$) in human alcoholic cirrhotic livers.

Immunohistochemistry evaluation revealed that GRHL2 was mostly localized to the biliary epithelium in normal human livers (FIGs. 7A-7C). Increased GRHL2 staining was detected within hepatocytes both in alcohol-fed mice and in livers of alcoholic patients (FIGs. 7A-7C). While, western blot analysis from total livers revealed only a moderate increase in
15 the expression of the 70 kDa GRHL2 (GRHL2-FL) (FIGs. 7D-7E), the levels of the 49kDa GRHL2 splice variant (GRHL2-S), previously described as a “dominant negative” variant, was significantly increased in both human and murine livers (FIGs. 7D-7E). To dissect the functional relevance of this finding, a luciferase reporter containing the human miR-122 promoter was cotransfected with either the GRHL2-FL or the GRHL2-S isoforms into Huh-7
20 cells. Results indicate that both the full-length (FL) and spliced variants of GRHL2 potentially inhibited miR-122 expression (FIG. 7F). Taken together, data indicate that alcohol regulates miR-122 expression by selectively increasing the spliced form of GRHL2 in hepatocytes (FIG. 8).

Immunohistochemistry (IHC) revealed that while GRHL1 staining is confined to
25 hepatocytes, no clear change in staining was apparent (FIG. 14A). GRHL2 staining revealed its expression is restricted to the biliary epithelium in healthy controls and pair-fed mice, however, alcoholic cirrhosis patients and alcohol-fed mice had notably increased staining within hepatocytes (FIG. 14B). IHC for GRHL2 of FFPE and immunofluorescence also showed that alcohol-fed mice had increased GRHL2 staining within hepatocytes (FIG. 14C).

30 Western blot from total liver lysates revealed that while GRHL1-FL was decreased in alcoholic patients (FIG. 15A), the expression of the GRHL2-FL was unchanged in either murine or human livers (FIG. 15C). However, expression of the spliced variants of both of GRHL1 and 2, previously described in the literature as dominant-negative isoforms, were significantly increased in both alcohol-fed murine and human alcoholic cirrhosis livers

(FIG. 15A-15D). These isoforms, are the result of alternative splicing events in exon 1 characteristic of the Grainyhead-family proteins which result in proteins containing the conserved C-terminal DNA binding and dimerization domains, but lacking N-terminal transactivation domain, thereby inhibiting transcriptional activity at its targeted binding sites (FIG. 13B). Taken together, these results indicate that alcohol increases the spliced or “dominant-negative”, variants of GRHL1 and 2 in hepatocytes, allowing them to hetero-dimerize, and repress miR-122 expression.

To examine the inhibitory effect of the spliced isoforms on miR-122, the promoter region of the human miR-122 gene was cloned into an empty PGL4 luciferase plasmid devoid of an enhancer or promoter. Furthermore, the putative GRHL binding site (FIG. 13A) was mutated, and a truncated promoter which contains the HNF binding sites but is 50 bp downstream of the GRHL site was created. Promoter constructs with either GRHL1-FL, GRHL2-FL, or the GRHL2-S alone and in combination were transfected into HUH-7 cells, which has the highest miR-122 expression of any hepatocyte cell line. Surprisingly, GRHL1, 2, and 2-S alone or in combination all inhibit miR-122 promoter activity equally (FIG. 16A). Furthermore, both the truncated and the reporter with the of mutated putative GRHL binding site not only enhanced baseline promoter activity and only blocked the inhibitory effect of GRHL1-FL, and not of either GRHL2 isoforms (FIG. 16A).

HUH-7 cells, while having high miR-122 expression, their levels are nearly 10-fold lower than primary human hepatocytes. Therefore, to confirm the abovementioned findings, either the GRHL1-FL, 2-FL or 2-S isoforms were transfected independently or in combination into primary human hepatocytes. 48-hours later, total RNA was collected and assayed for pri-miR-122 expression. Oddly, neither GRHL1, GRHL2-FL, or the GRHL2-S inhibited pri-miR-122, while the combination of GRHL1 and GRHL2/GRHL2-S both enhanced expression (FIG. 16B). Taken together these data indicate that alcohol regulates miR-122 expression by selectively increasing the spliced forms of GRHL1 and 2 in hepatocytes.

Materials and Methods

Construction of miR-122 antagonist and overexpression plasmids

The scAAV-anti-miR-122 TuD and scAAV-anti-SCR TuD constructed were made as previously described. The BamHI fragment carrying anti-miR-122 TuD was replaced with the pri-miR-122 sequence amplified from C57/b6 mouse genome DNA to generate scAAV-pri-miR-122 construct (pri-miR-122F, GCGGGATCCGACTGCAGTTTCAGCGTTTGG

(SEQ ID NO: 1) and pri-miR-122R,
CGCGGATCCAAAAAAGACTCTAGGGCCCGACTTTACA (SEQ ID NO: 2)).

Construction of miR-122 promoter plasmids

5 The human mir-122 promoter element were made by insertion of a 1.5 kb amplified sequence from human genomic DNA into a PGL4 plasmid.

ChIP

Recombinant human GRHL2 with a GST was expressed in huh-7 cells. Chomamtin
10 immunoprecipitation was performed according to manufacturer instructions (17-295 Millipore). Briefly, nuclear lysates were sonicated using Biorupter (Diagenode). Sheared chromatin was incubated over night at 4°C with either Rabbit IgG (sc-2027, Santa Cruz Biotechnology) or Anti-GST (ab19256, Abcam) antibody. The following day, pulldown of the antibody-chromatin complex was performed using Biorad Protein A Surebeads. DNA
15 purification was performed using QIAquick PCR Purification Kit (28104, Qiagen). qPCR was performed using primers specific for the putative GRHL2 human miR-122 promoter locus.

Animal use

20 Mice were gradually acclimated to a Lieber-DeCarli liquid diet with 5% ethanol (vol/vol) over a period of 1 week, then maintained on the 5% diet for 4 weeks. Consumption was recorded daily and isocaloric amounts of a control diet (in which dextran-maltose replaced calories from ethanol) were dispensed to pair-fed (PF) animals. Weights were recorded weekly. Wild-type (WT) mice (C57/Bl6), Alb-Cre, and HIF-1flox/flox mice were
25 purchased from Jackson Laboratories (Bar Harbor, ME). Mice were treated by tail vein injection with AAV vectors at 6×10^{11} genome copies/mouse or approximately 3×10^{13} genome copies/kg.

Detection of pri-miR-122

30 Total liver cDNA was generated as stated above. Taqman Primer and probes specific for mmu-pri-miR-122-FAM, hsa-pri-miR-122-FAM were purchased from Applied Biosystems. Human-GAPDH-Hex (applied Biosystems), or mouse-GAPDH-Hex (Bio-Rad), were multiplexed with target genes for normalization.

MiRNA Analysis

Reverse transcription (30 min - 16°C; 30 min - 42°C; 5 min - 85°C) was performed in Eppendorf Mastercycler (Eppendorf, New York, USA) using 10 ng RNA, TaqMan primers and miRNA Reverse Transcription Kit (APPLIED BIOSYSTEMS) followed by quantitative RT- in CFX96 (Bio-Rad) using TaqMan Universal Probes Master Mix (Biorad). All tissue results were normalized to snoRNA202, or U6 expression based on Normfinder (moma.dk/normfinder-software) results. miR-122-FAM, U6-FAM, and sno202-FAM primer sets were purchased from Applied Biosystems.

Confocal microscopy – Immunofluorescence.

Confocal images were processed as previously described. Primary hepatocytes were fixed, permeabilized and stained O/N with either anti-GRHL2 (Atlas antibodies, HPA004820), or normal Rabbit IgG sc-2027 (Santa Cruz Biotechnology). Actin was stained using ActinGreen 488 anti-ReadyProbes Reagent #R37110 (Molecular Probes). Secondary antibody used was anti-rabbit Alexa Fluor 594 #A-21207 (Molecular Probes). Images were acquired using Leica TCS SP5 II Laser Scanning Confocal Microscope.

Statistical Analysis

Statistical significance was determined using two-tailed t-test; ANOVA and Dunnett's multiple comparison post-test were used to compare the means of multiple groups. Outliers were determined using ROUT method and a q of 1%. Data are shown as mean $\pm$ SEM and were considered statistically significant at $P < 0.05$. GraphPad Prism 6.02 (GraphPad Software Inc.) was used for analysis.

Isolation of primary mouse hepatocytes and LMNCs

Anesthetized animals were perfused by way of portal vein with saline solution, followed by enzymatic digestion, as previously described. The hepatocytes were separated by centrifugation, and LMNCs were purified by centrifugation in Percoll gradient followed by CD45+ microbead selection using MACS LS columns (MACS).

In vitro experiments. Primary hepatocytes were cultured in low-glucose DMEM supplemented with 10% fetal bovine serum, 1% Anti-Anti, 1% insulin, transferrin, selenium solution. Primary hepatocytes were seeded in 6-well collagen-coated plates (Biocoat, Becton Dickinson). Before starting stimulation experiments, hepatocytes were rested for 4 hours.

Biochemical Assays and cytokines

Serum alanine aminotransferase (ALT) levels were determined using a commercially available reagent (Advanced Diagnostics Inc) as described. Liver triglycerides were extracted using a 5% NP-40 lysis solution buffer. Triglycerides were quantified using a commercially available kit (Wako Chemicals) followed normalization to protein amount by BCA protein assay (Pierce).

ELISA

Cytokine levels were monitored in liver whole cell lysates diluted in assay diluent following manufacturer instructions. MCP-1 and TNF α were measured by use of specific anti-mouse ELISA from BioLegend. IL-1 β was measured by use of specific anti-mouse ELISA (R&D Systems) that recognizes pro-IL-1 β and cleaved IL-1 β .

EMSA

The DNA binding activity of HIF-1 α was assessed by electrophoretic mobility shift assay as described previously. Briefly, nuclear protein extract from liver (5 μ g) was incubated with 50,000 cpm γ^{32} P-labeled HIF-1 α consensus oligonucleotide at room temperature for 30 min. All reactions were run on a 4% polyacrylamide gel, and the dried gel was exposed to an X-ray film at -80°C for different times. For the cold competition reaction, a 20-fold excess of same, unlabeled, double-stranded oligonucleotide was added to the reaction mixture before adding the labeled oligonucleotide probe.

RNA extraction and real-time PCR

Total RNA was extracted using the Quiagen miRNeasy kit (Quiagen) according to the manufacturer's instructions. Briefly, tissue samples were lysed in QIAzol Lysis reagent (Qiagen), homogenized with stainless steel beads in TissueLyser II (Qiagen) followed by miRNA isolation following manufacturer's instructions and DNase 1 Digest. RNA was quantified using Nanodrop 2000 (Thermo Scientific). Complementary DNA (cDNA) synthesis was performed by reverse transcription of 1 μ g total RNA using the iScript Reverse Transcription Supermix (BIO-RAD). Real-time quantitative PCR was performed using Bio-Rad iTaq Universal SYBR Green Supermix and a CFX96 real-time detection system (Bio-Rad Laboratories). Primers were synthesized by IDT, Inc. The primer sequences are listed in Table 2 below. Relative gene expression was calculated by the comparative cycle threshold

(Ct) method. The expression level of target genes was normalized to the house-keeping gene, 18S rRNA, in each sample and the fold-change in the target gene expression between experimental groups was expressed as a ratio. Melt-curve analysis was used to confirm the authenticity of the PCR products.

5

Western blot analysis

Whole cell lysates, nuclear and cytoplasmic extracts were prepared from mouse livers as described previously. All westerns were performed under reducing conditions using tris-glycine buffer system and blotted to nitrocellulose membranes. Proteins of interest were
10 detected by immunoblotting with specific primary antibodies against; GRHL2 (Atlas antibodies, HPA004820), beta-actin-HRP (ab9482; Abcam). Respective horseradish peroxidase-labeled secondary antibodies were from Santacruz Biotechnonology. The specific immunoreactive bands of interest were detected by chemiluminescence (Biorad) The immunoreactive bands were quantified by densitometric analysis using an UVP System (Bio-
15 Rad Laboratories, Hercules, CA).

Histopathological analysis

Sections of formalin-fixed, paraffin-embedded livers were stained with hematoxylin and eosin (H&E), or Sirius Red and assessed for histological features of steatosis,
20 inflammatory cell invasion, and fibrosis. The H&E and Sirius Red stained sections were independently examined by a 2 pathologists in a blinded manner. Immunohistochemistry staining for GRHL2 (Atlas antibodies, HPA004820) were performed on formalin-fixed, paraffin-embedded livers according to the manufacturer's instructions. ImageJ (NIH) was used for image analysis.

25

Table 1. Demographic and patient data from human samples.

	Alcoholic Patients	Hepatitis C Patients
N	10	12
Age, years	51 (39 - 66)	56 (41 - 69)
Sex, Male/Total	9/10	6/12
Race	White (10/10)	White (9/12), Black (1/12), Hispanic (1/12), American Indian or Alaskan (1/12)
MELD	31 (22 - 40)	28 (12 - 39)
Prothrombin Time (INR)	2.49 (1.50 - 3.24)	2.1 (1.23 - 3.18)
Total Bilirubin (mg/dl)	5.15 (1.50 - 20.60)	3.70 (1.50 - 42.20)
Creatinine	2.13 (1.01 - 4.04)	1.29 (0.63 - 5.34)
AST, IU/L	41.50 (30.00 - 1425.00)	80.00 (40.00 - 286.00)
ALP, IU/L	163.50 (84.00 - 326.00)	105.00 (60.00 - 219.00)
Albumin, g/dL	3.30 (2.70 - 4.70)	2.70 (2.00 - 3.60)
Years since abstinence	0.67 (0.083 - 2)	12 (4 - 20)
Months since last drink	8.00 (1 - 24)	0 (0 - 240)
Collection type	Transplant (10/10)	Transplant (10/10)
Primary diagnosis	Alcoholic cirrhosis (10/10)	Chronic active hepatitis, type C (10/10)
Hepatitis A, IgG+ /Total available	4/10	7/10
Hepatitis B core, IgG+ /Total available	0/10	4/11
Hepatitis B surface, IgG+ /Total available	2/10	4/11
Hepatitis C, IgG+ /Total available	0/10	12/12
HIV 1 and 2, IgG+ /Total available	1/10	0/10
CMV, IgG+ /Total available	5/10	11/12
EBV, IgG+ /Total available	10/10	12/12
Pathology report: Evidence of Dysplasia	0/10	0/10

Table 2. Primers used, all are listed in 5' to 3'.

Table 2:	Primers used in this study			
Gene	Forward Primer – 5'-3'	SEQ ID NO:	Reverse primer – 5'-3'	SEQ ID NO:
mTNF α	CACCACCATCAAGGACT CAA	3	AGGCAACCTGACCACTCTC C	17
mMCP-1	CAGGTCCCTGTCATGCT TCT	4	CAGGTCCCTGTCATGCTTC T	18

mActa2	GTCCCAGACATCAGGGA GTAA	5	TCGGATACTTCAGCGTCAG GA	19
mTGFβ	ATTCTGGCGTTACCTT G	6	CTGTATTCCGTCTCCTTGGT T	20
mCollagen1a 1	GCTCCTCTTAGGGGCCA T	7	CCACGTCTCACCATTGGG	21
mHIF1α	CAAGATCTCGGC GAAGCA A	8	GGTGAGCCTCATAACAGAA GCTTT	22
mHNF4	AGCTCGAGGCTCCGTAG TGTTT	9	GAAAATGTGCAGGTGTTGA CCA	23
mF4/80	TGCATCTAGCAATGGAC AGC	10	GCCTTCTGGATCCATTTGA A	24
mCD68	CCCACAGGGCAGCACA GTGGAC	11	TCCACAGCAGAAGCTTTGG CCC	25
mIL-1B	CTTTGAAGTTGACGGAC CC	12	TGAGTGATACTGCCTGCCT G	26
mHNF6	TTCCAGCGCATGTCGGC GCTC	13	GGTACTAGTCCGTGGTTCT TC	27
mPPAR-γ	GGAAGACCACTCGCATT CCTT	14	TCGCACTTTGGTATTCTTGG AG	28
m/h18s	GTAACCCGTTGAACCCC ATT	15	CCATCCAATCGGTAGTAGC G	29
hGRHL2	GAAAGTCCAGTTTCACC AGAGG	16	GGCACTAAGGCCACTAGTC TTTT	30

CLAIMS

What is claimed is:

1. A method for modulating miR-122 expression in a cell, the method comprising:
5 contacting a cell with an effective amount of a grainyhead-like transcriptional regulator (GRHL) modulating agent.
2. The method of claim 1, wherein the GRHL modulating agent modulates grainyhead-like 1 (GRHL1), grainyhead-like 2 (GRHL2), and/or grainyhead-like 3 (GRHL3)
10 transcriptional regulator.
3. The method of claim 1 or 2, wherein the GRHL modulating agent modulates grainyhead-like 2 (GRHL2) transcriptional regulator, optionally spliced GRHL2.
- 15 4. The method of any one of claims 1 to 3, wherein the cell is a hepatocyte.
5. The method of claim 4, wherein the hepatic cell is a parenchymal hepatocyte, non-parenchymal hepatocyte, sinusoidal endothelial cell, Kupffer cell, hepatic stellate cell, or intrahepatic lymphocyte.
20
6. The method of any one of claims 1 to 4, wherein the grainyhead-like (GRHL) modulating agent is a protein or a nucleic acid.
7. The method of any one of claims 1 to 6, wherein the grainyhead-like (GRHL)
25 modulating agent is an inhibitory nucleic acid
8. The method of claim 7, wherein the inhibitory nucleic acid inhibits expression of a grainyhead-like transcriptional regulator (GRHL) resulting in an increase in expression of miR-122.
30
9. The method of claim 7, wherein the inhibitory nucleic acid is selected from the group consisting of dsRNA, siRNA, shRNA, pri-miRNA, miRNA, and artificial miRNA (amiRNA).

10. The method of claim 9, wherein the miRNA or amiRNA is a tough decoy (TUD) miRNA.

11. The method of any one of claims 6 to 10, wherein the nucleic acid is flanked by adeno-associated virus (AAV) inverted terminal repeats (ITRs).

12. The method of claim 11, wherein the nucleic acid is encapsidated by one or more adeno-associated virus (AAV) capsid protein.

13. The method of claim 12, wherein the one or more capsid protein is a liver-trophic capsid protein.

14. The method of claim 12, wherein the one or more capsid protein is an AAV2, AAV3, AAV3b, AAV7, AAV8, or AAV9 capsid protein.

15. A method for treating a liver-associated disease, the method comprising: administering to a subject having or suspected of having a liver-associated disease an effective amount of an agent that increases expression of miR-122 in liver cells of the subject.

16. The method of claim 15, wherein the agent is an inhibitor of a grainyhead-like (GRHL) transcriptional regulator, or a nucleic acid engineered to express miR-122.

17. The method of claim 15 or 16, wherein the agent inhibits expression of grainyhead-like 2 (GRHL2) transcriptional regulator, optionally spliced GRHL2.

18. The method of any one of claims 15 to 16, wherein the subject is a mammal, optionally a human.

19. The method of any one of claims 15 to 17, wherein the liver-associated disease is characterized by a decrease in miR-122 expression relative to a subject not having the liver-associated disease.

20. The method of any one of claims 15 to 19, wherein the liver-associated disease is alcoholic liver disease (ALD), cirrhosis, hepatitis A, hepatitis B, hepatitis C, hepatocellular carcinoma (HCC), or fibrosis of the liver.

5 21. The method of any one of claims 16 to 20, wherein the inhibitor of grainyhead-like (GRHL) transcriptional regulator increases miR-122 expression in the subject.

22. The method of any one of claims 16 to 20, wherein the inhibitor of grainyhead-like (GRHL) transcriptional regulator or the nucleic acid engineered to express miR-122
10 decreases HIF-1 α expression in the subject.

23. The method of any one of claims 16 to 22, wherein the inhibitor of grainyhead-like (GRHL) transcriptional regulator is a protein or a nucleic acid.

15 24. The method of claim 23, wherein the nucleic acid is an inhibitory nucleic acid.

25. The method of claim 24, wherein the inhibitory nucleic acid is selected from the group consisting of dsRNA, siRNA, shRNA, pri-miRNA, miRNA, and artificial miRNA (amiRNA).
20

26. The method of claim 25, wherein the miRNA or amiRNA is a tough decoy (TUD) miRNA.

27. The method of any one of claims 16 to 26, wherein the inhibitor of grainyhead-like (GRHL) transcriptional regulator or the nucleic acid engineered to express miR-122 is
25 administered to the subject in a recombinant adeno-associated virus (rAAV).

28. The method of claim 27, wherein the rAAV comprises one or more AAV capsid protein.
30

29. The method of claim 28, wherein the one or more capsid protein is a liver-trophic capsid protein.

30. The method of claim 29, wherein the one or more capsid protein is an AAV2, AAV3, AAV3b, AAV7, AAV8, or AAV9 capsid protein.

31. A method for treating a liver-associated disease, the method comprising:

5 administering to a subject having or suspected of having a liver-associated disease an effective amount of a recombinant adeno-associated virus comprising a transgene encoding miR-122.

32. The method of claim 31, wherein the subject is a mammal, optionally a human.

10 33. The method of claim 31 or 32, wherein the liver-associated disease is alcoholic liver disease (ALD), cirrhosis, hepatitis A, hepatitis B, hepatitis C, hepatocellular carcinoma (HCC), or fibrosis of the liver.

15 34. The method of any one of claims 31 to 33, wherein the transgene encoding miR-122 comprises a sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2 or a functional fragment thereof.

20 35. The method of any one of claims 31 to 34, wherein the rAAV comprises a liver-trophic capsid protein.

36. The method of claim 35, wherein the capsid protein is an AAV2, AAV3, AAV3b, AAV7, AAV8, or AAV9 capsid protein.

25 37. A method for inhibiting hypoxia-inducible factor 1 α (HIF-1 α) expression in a liver cell of a subject having a liver-associated disease, the method comprising increasing expression of miR-122 in the cell.

30 38. The method of claim 37, wherein the liver-associated disease is the liver-associated disease is alcoholic liver disease (ALD), cirrhosis, hepatitis A, hepatitis B, hepatitis C, hepatocellular carcinoma (HCC), or fibrosis of the liver.

39. The method of claim 37, wherein the liver-associated disease results in hepatic lipid accumulation in the subject.

40. The method of claim 37, wherein the cell is a hepatocyte.

41. The method of claim 40, wherein the hepatic cell is a parenchymal hepatocyte, non-
5 parenchymal hepatocyte, sinusoidal endothelial cell, Kupffer cell, hepatic stellate cell, or
intrahepatic lymphocyte.

42. The method of claim 37, wherein expression of miR-122 is increased in the cell by
delivering to the cell a nucleic acid engineered to express miR-122, or an inhibitory nucleic
10 acid that inhibits expression of a grainyhead-like transcriptional regulator (GRHL).

43. The method of claim 42, wherein the nucleic acid comprises a transgene encoding
miR-122 and is flanked by adeno-associated virus (AAV) inverted terminal repeats (ITRs).

44. The method of claim 43, wherein the nucleic acid is encapsidated by one or more
15 adeno-associated virus (AAV) capsid protein.

45. The method of claim 44, wherein the one or more capsid protein is a liver-trophic
capsid protein.

46. The method of claim 44, wherein the one or more capsid protein is an AAV2, AAV3,
AAV3b, AAV7, AAV8, or AAV9 capsid protein.




FIG. 1C




FIG. 1B




FIG. 1A




FIG. 1D




FIG. 1E

3/44





FIG. 1F

4/44




FIG. 2A




FIG. 2B




FIG. 2C




FIG. 2D

7/44




FIG. 2E




FIG. 2F

8/44




FIG. 3A




FIG. 3B




FIG. 3C




FIG. 3D




FIG. 3E




FIG. 4A

12/44




FIG. 4B




FIG. 4C

14/44




FIG. 5A




FIG. 5B





FIG. 5C




FIG. 5D

17/44




FIG. 5E




FIG. 6C




FIG. 6B




FIG. 6A





FIG. 6E

FIG. 6D

20/44

**FIG. 6F**




FIG. 7A




FIG. 7B




FIG. 7C





FIG. 7D

24/44




FIG. 7E




FIG. 7F





FIG. 8


26/44

Human Data and HIF1 regulation


**FIG. 9A**

27/44

Human Data and HIF1 regulation Hif-1 α

**FIG. 9B**

Histology scoring and cytokines in WT and HIFKO mice

**FIG. 10A**




FIG. 10B




FIG. 10C




FIG. 10D




FIG. 10E

30/44




FIG. 10F






FIG. 10G

**FIG. 11A****FIG. 11B**




FIG. 11C




FIG. 11D

33/44




FIG. 11E




FIG. 11F




FIG. 12A




FIG. 12B




FIG. 12C




FIG. 13A

36/44






FIG. 13B

37/44



GRHL1

FIG. 14A



GRHL2

FIG. 14B

38/44




FIG. 14C

39/44




FIG. 15A

40/44





FIG. 15B




FIG. 15C

42/44




FIG. 15D

miR-122 Promoter Activity in HUH-7 cells




FIG. 16A

44/44




FIG. 16B

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US17/26217

Box No. 1 Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
 - a. ☒ forming part of the international application as filed:
 - ☒ in the form of an Annex C/ST.25 text file.
 - ☐ on paper or in the form of an image file.
 - b. ☐ furnished together with the international application under PCT Rule 13ter.1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.
 - c. ☐ furnished subsequent to the international filing date for the purposes of international search only:
 - ☐ in the form of an Annex C/ST.25 text file (Rule 13ter.1(a)).
 - ☐ on paper or in the form of an image file (Rule 13ter.1(b) and Administrative Instructions, Section 713).
2. ☐ In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US17/26217

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☒ Claims Nos.: 4-14, 19-30, 34-36
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US17/26217

A. CLASSIFICATION OF SUBJECT MATTER

IPC - C12N 15/113, 15/861, 15/86, 15/85; A61K 31/7105, 31/713, 48/00, 47/42; A61P 1/16 (2017.01)
 CPC - C12N 15/1136, 15/113, 15/8616, 15/861, 15/86, 15/85; A61K 48/005, 48/0058, 47/48346, 47/42, 31/7105, 31/713

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

See Search History document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

See Search History document

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

See Search History document

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	(TANIMIZU, N et al.) Downregulation of miR122 by grainyhead-like 2 restricts the hepatocytic differentiation potential of adult liver progenitor cells. Development. December 2014, Vol. 141, No. 23; pages 4448-4456; page 4451, 2nd column, 4th paragraph; Figure 7B; page 4455, 1st column, 2nd paragraph; DOI: 10.1242/dev.113654	1-2, 3/1-2 --- 17/15-16
X --- Y	US 2013/0142861 A1 (NATIONAL YANG MING UNIVERSITY) June 06, 2013; paragraphs [0030]-[0041]	15-16, 18/15-16, 31-33 --- 17/15-16
X --- Y	(CSAK, T et al.) micro RNA-122 regulates hypoxia-inducible factor-1 and vimentin in hepatocytes and correlates with fibrosis in diet-induced steatohepatitis. Liver International. February 2015, Vol. 35, No. 2; pages 532-541; page 534, 2nd column, 2nd paragraph; Figure 1A; page 536, 2nd column, 2nd paragraph; page 537, 1st column, 1st paragraph and 2nd column, 2nd paragraph; Figure 3B; Figure 4A; DOI: 10.1111/liv.12633	37-42 --- 43-46
Y	US 2010/0186103 A1 (GAO, G ET AL.) July 22, 2010; paragraphs [0012], [0023], [0031]-[0032], [0081], [0085], [0105], [0138]	43-46
A	(HSU, SH et al.) Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. Journal of Clinical Investigation. August 2012, Vol. 122, No. 8; pages 2871-2883; DOI: 10.1172/JCI63539	1-2, 3/1-2, 15-16, 17/15-16, 18/15-16, 31-32, 33/31-32, 37-46

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

12 June 2017 (12.06.2017)

Date of mailing of the international search report

05 JUL 2017

Name and mailing address of the ISA/

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
 P.O. Box 1450, Alexandria, Virginia 22313-1450
 Facsimile No. 571-273-8300

Authorized officer

Shane Thomas

PCT Helpdesk: 571-272-4300
 PCT OSP: 571-272-7774